EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR ‐ PSP )

Prashanth Lingappa Kukkle iD, Divyani Garg iD, Jacky Ganguly iD, Soaham Desai iD, Rukmini Mridula Kandadai, Sahil Mehta, Pettarusp Murzban Wadia, Deepika Joshi iD, Lulup Sahoo, Vijayashankar Paramanandam, Taallapalli Ashok Vardhan Reddy, Adreesh Mukherjee iD und 20 weitere

Movement Disorders Clinical Practice · 2026

DOI: 10.1002/mdc3.70672 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Prashanth Lingappa Kukkle und 31 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease and Movement Disorders Clinic, Bangalore, India. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progressive supranuclear palsy (PSP) is a rare and devastating tauopathy with limited global data. Given India's large population, genetic diversity, and clinical heterogeneity, large multicenter datasets are crucial to enrich global understanding of PSP.

Objective

To characterize the demographic, clinical, and phenotypic profiles of a large multicenter Indian PSP cohort.

Methods

Subjects fulfilling MDS‐PSP criteria were prospectively recruited across movement disorders centers (2021–2025). Standardized demographic and clinical data were collected.

Results

A total of 1035 subjects were enrolled (M:F = 709:326), with a median age of 65 years and a mean onset age of 62.2 ± 7.9 years. Regional distribution reflected pan‐Indian recruitment (South 35%, North 26%, West 21%, East 18%). PSP‐Richardson's syndrome was most common (41%), followed by PSP‐Parkinsonism (18%) and PSP‐CBS (11%); rarer phenotypes included PSP‐PI (7%), PSP‐F (7%), PSP‐PGF (5%), PSP‐OM (2%), PSP‐SL (1%), and PSP‐C (1%). Falls occurred earliest in PSP‐PGF (13.7 months) and PSP‐SL (16.3 months), while PSP‐P showed delayed disability (falls at 31 months) indicating progression patterns. Cognitive onset was prominent in PSP‐F (21%) and PSP‐SL (57%). Levodopa was prescribed to 893 patients; 186 (21%) reported >25% subjective benefit, and 358 (40%) reported ≤25% benefit. Amantadine was used in 351 (34%) patients, with improvement in 177.

Conclusion

This largest systematically profiled PSP cohort highlights both shared and distinctive features: high frequency of non‐RS variants, aggressive course in PSP‐RS/SL, better survival in PSP‐P, and limited pharmacological benefit. These findings establish a foundation for longitudinal and genetic studies in diverse populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Supranuclear Palsy, ProgressiveHumansIndiaFemaleAgedMaleMiddle AgedCohort StudiesPhenotypeProspective Studies

Stichwörter der Autor:innen

IndiaTauopathyclinical profileprogressive supranuclear palsy

Autor:innen und Institutionen

  • Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.
  • Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
  • Institute of Neurosciences Kolkata, Kolkata, India.
  • Shree Krishna Hospital Pramukhswami Medical College Bhaikaka University, Karamsad Anand, India.
  • Department of Neurology, Zydus Hospital, Anand, India.
  • Parkinson's disease and Movement Disorders Center, Yashoda Hospitals, Hyderabad, India.

ORCID-Profile: Prashanth Lingappa Kukkle, Divyani Garg, Jacky Ganguly, Soaham Desai, Deepika Joshi, Adreesh Mukherjee, Charulata Sankhla, Pankaj Agarwal, Mitesh Chandarana, Ravi Gupta, Huw Morris

Förderung

  • Michael J. Fox Foundation for Parkinson's Research

Zitieren

APA

Kukkle, P. L., Garg, D., Ganguly, J., Desai, S., Kandadai, R. M., Mehta, S., Wadia, P. M., Joshi, D., Sahoo, L., Paramanandam, V., Reddy, T. A. V., Mukherjee, A., Krishnan, S., Shetty, K., Sankhla, C., Agarwal, P., Shah, H. S., Bhowmick, S., Chandarana, M., …, & Parkinson's Research Alliance of India (PRAI) and the Global Parkinson's Genetic Program (GP2) (2026). Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR ‐ PSP ). Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70672

Vancouver

Kukkle PL, Garg D, Ganguly J, Desai S, Kandadai RM, Mehta S, et al. Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR ‐ PSP ). Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70672

BibTeX
@article{Kukkle2026,
  author = {Kukkle, Prashanth Lingappa and Garg, Divyani and Ganguly, Jacky and Desai, Soaham and Kandadai, Rukmini Mridula and Mehta, Sahil and Wadia, Pettarusp Murzban and Joshi, Deepika and Sahoo, Lulup and Paramanandam, Vijayashankar and Reddy, Taallapalli Ashok Vardhan and Mukherjee, Adreesh and Krishnan, Syam and Shetty, Kuldeep and Sankhla, Charulata and Agarwal, Pankaj and Shah, Heli S and Bhowmick, Suvorit and Chandarana, Mitesh and Venkata, Malini and Geetha, Thenral S and Menon, Ramesh and Charugulla, Sandeep and Murugan, Sakthivel and Gupta, Ravi and Kumar, Niraj and Biswas, Atanu and Kumar, Hrishikesh and Borgohain, Rupam and Morris, Huw and Ramprasad, Vedam L and Parkinson's Research Alliance of India (PRAI) and the Global Parkinson's Genetic Program (GP2), Parkinson's Research Alliance of India (PRAI) and the Global Parkinson's Genetic Program (GP2)},
  title = {Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR ‐ PSP )},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70672}
}
Kostenlos starten →